AtriCure (NASDAQ:ATRC) Director Maggie Yuen Sells 3,500 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at approximately $538,456.30. The trade was a 19.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

AtriCure Stock Up 4.8%

Shares of ATRC opened at $41.39 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a 50-day simple moving average of $32.25 and a 200-day simple moving average of $31.38. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $43.18. The firm has a market capitalization of $2.11 billion, a P/E ratio of 197.10 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ATRC shares. Weiss Ratings raised AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Wall Street Zen cut AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Canaccord Genuity Group lifted their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Finally, Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $48.50.

Institutional Investors Weigh In On AtriCure

Institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure in the 2nd quarter valued at approximately $37,000. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure in the 2nd quarter worth approximately $40,000. Smartleaf Asset Management LLC lifted its position in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the period. Fifth Third Bancorp bought a new position in shares of AtriCure during the 1st quarter worth approximately $51,000. Finally, Global Retirement Partners LLC acquired a new stake in AtriCure in the 2nd quarter valued at $52,000. 99.11% of the stock is owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.